LGND
Ligand Pharmaceuticals Incorporated
303.00$
+0.1%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.3% | 25.3% | 60.3% | 32.1% | 70.5% | 66.5% | -56.3% | 33.2% | 11.3% | 76.8% | 94.1% | 37.7% | 45.3% | |
| 26.2% | 33.6% | 28.3% | 21.3% | 14.1% | 20.2% | 20.6% | 18.8% | 5.9% | 16.1% | 15.9% | 12.9% | 11.3% | |
| 20.9% | 20.4% | 23.7% | 26.6% | 50.6% | 17.6% | 17.3% | 21.0% | 12.8% | 23.9% | 20.5% | 21.4% | 18.3% | |
| -63.4% | -56.9% | 26.6% | -18.3% | -1.2% | 27.1% | -11.4% | -13.0% | -9.2% | 15.6% | 11.4% | -11.0% | -0.8% | |
| 1.5% | 1.5% | 0.3% | 5.2% | 27.5% | 1.7% | 0.5% | 0.4% | 0.0% | 0.0% | 0.4% | 0.0% | 0.1% | |
| -59.3% | -36.6% | -12.2% | -131.9% | -89.8% | -90.2% | 10.8% | -22.4% | -306.1% | -30.3% | -182.4% | 504.2% | -49.8% | |
| -0.3% | -0.9% | -9.9% | – | – | – | – | – | -13.0% | 0.0% | – | -94.2% | – | |
| – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 300.3% | 11.6% | 0.0% | 1,099.0% | 362.6% | |
| 9.9% | 22.3% | 39.5% | 22.9% | 106.3% | 47.6% | -10.3% | 31.5% | 354.8% | 14.0% | -27.3% | 857.9% | 327.1% | |
| -26.1% | 13.1% | 87.6% | -76.9% | 87.8% | 20.3% | -53.6% | 41.3% | 62.1% | 59.6% | -115.7% | 1,399.9% | 323.2% | |
| 21.8% | 23.8% | 60.0% | 26.9% | 43.0% | 64.8% | -56.8% | 32.7% | 11.3% | 76.8% | 93.7% | 37.7% | 45.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.